

糖尿病
レポート①

糖尿 I 型糖尿病の
幹細胞治療効果

Anil Bhansali ,et al.
Efficacy and Safety of Autologous
Bone Marrow-Derived Stem Cell
Transplantation in Patients With
Type 2 Diabetes Mellitus: A
Randomized Placebo-Controlled
Study
: Cell Transplantation, Vol. 23, pp.
1075-1085, 2014

Table 5. Comparison of Parameters Between Cases and Controls

Parameters	Cases (Group I)		Controls (Group II)		<i>p</i> Value	
	6 Months	12 Months	6 Months	12 Months	6 Months	12 Months
Δ Insulin dose	-25.0 (-36.0 to -18.5)	-31.0 (-38.0 to -20.0)	-9.5 (-13.5 to -6.0)	-9.5 (-13.0 to -5.5)	0.001	0.004
Δ HbA1c (%)	0.0 (0.0 to 0.0)	0.6 (-0.1 to 0.9)	0.4 (-0.2 to 1.0)	0.1 (0.0 to 0.9)	0.552	0.836
Δ FPI (μU/ml)	-3.1 (-16.9 to 2.0)	-0.1 (-11.0 to 3.1)	3.6 (1.5 to 5.1)	2.1 (1.2 to 13.0)	0.169	0.396
Δ HOMA-IR (%)	-1.7 (-7.0 to -1.0)	-0.2 (-4.6 to 0.8)	0.6 (-0.3 to 3.8)	1.2 (-7.0 to 4.1)	0.044	0.113
Δ HOMA-β (%)	2.4 (-39.8 to 23.1)	-11.6 (8.8 to 45.3)	-4.9 (-13.8 to 3.1)	-22.3 (-51.9 to 0.2)	0.722	0.079
Δ Stimulated C-pep (ng/ml)	1.3 (0.6 to 3.7)	1.8 (0.8 to 2.6)	-0.0 (-0.6 to 0.4)	0.3 (0.1 to 0.5)	0.041	0.032

+Increase from baseline, -Decrease from baseline. All values are expressed as median and interquartile range and have been recalculated for each individual patient.